To compare seroconversion using hepatitis B vaccine between hemodialysis (HD) and peritoneal dialysis (PD) patients.
Design
Data on PD patients vaccinated were collected retrospectively for the period 1992 to 1995. The data on HD patients were collected prospectively from 1991 to 1994.
Setting
A university outpatient dialysis center.
Participants
All adult patients who received all four doses of hepatitis B vaccine while on dialysis were included (47 PD and 50 HD patients).
Intervention
Recombinant hepatitis B vaccine (Engerix), 40 μg IM was administered at 0, 1, 2, and 6 months.
Main Outcome Measure
Seroconversion was measured after completion of the vaccination series.
Results
74% of the HD patients seroconverted compared to 53 % of PD patients (p = 0.03). Older, heavier patients compared to all the other patients had a lower seroconversion rate in both the HD patients (55 % vs. 78 %) and PD patients (38 % vs. 59 %) (p = 0.03).
Conclusion
The seroconversion rate to recombinant hepatitis B vaccine is lower in patients on PD than on HD for unclear reasons. Further studies are required to determine the etiology of this difference.
Descamps-LatschaB., HerbelinA., NguyenA.T., ZingraffJ., JungersP., ChatenoudL.Immune system dysregulation in uremia.Semin Nephrol1994; 14: 253–60.
2.
ChatenoudL., JungersP., Descamps-LatschaB.Immunological considerations of the uremic and dialysed patient.Kidney Int1994; 45(Suppl): S92–6.
3.
StepheneJ.Recombinant versus plasma derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness.Vaccine1988; 6: 209–303.
4.
AlterH.J., PurcellR.H., GerinJ.L.Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen- positive saliva and semen.InfectImmun1977; 16: 928–33.
5.
BancroftW.H., SnitbhanR., ScottR.M.Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen.J Infect Dis1977; 135: 79–85.
6.
GoodmanW., GallagherN., SherrardD.Peritoneal dialysis fluid as a source of hepatitis antigen.Nephron1981; 29: 107–9.
VasS.I., OreopoulosD.G.Handle with care: hepatitis B antigen carriers in peritoneal dialysis units.Nephron1981; 29: 106–7.
9.
FlemingS.J., MoranD.M., CooksleyW.G.E., FaoagliJ.L.Poor response to a recombinant hepatitis B vaccine in dialysis patients.JInfect1991; 22: 251–7.
10.
Van GeelenJ.A., SchalnS.W., De VisserE.M., HeijtinkR.A.Immune response to Hepatitis B vaccine in hemodialysis patients.Nephron1987; 45: 216–8.
11.
SteketeeR.W., ZiarnikM.E., DavisJ.P.Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers.Wis Am J Epidemiol1988; 127: 772–82.
12.
SchmidE., AugustinR., MachleidtC., WisserH., KuhlmanU.Efficacy of hepatitis B vaccination in patients on CAP D compared to patients on hemodialysis. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in Peritoneal DialysisToronto: Peritoneal Dialysis Publications, 1987; 3: 61–5.
KohlerH., ArnoldW., RenschinG., DormeyerH., MyerZum, BuscgenfeldeK.H.Active hepatitis B vaccination of dialysis patients and medical staff.Kidney Int1984; 25: 124–8.
15.
CrosnierJ., JungersP., CourouceA.M., LaplancheA., BenhamouE., DegosF., LacourB., PrunetP., CerisierY., GuesryP.Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French hemodialysis units.Lancet1981; 1: 797–800.
16.
BommerJ., GrussendorfM., JilgW., DeinhardtF., KochH.G., DaraiG., BommerG., RambausekM., RitzE.Vaccination against hepatitis B in patients with renal insufficiency.Proc Eur Dial Transplant Assoc Eur Ren Assoc1985; 21: 300–5.
17.
DienstagJ.L., WernerB.G., PolkF.Hepatitis Bvaccine in health care personnel: safety, immunogenicity and indicators of efficacy.Ann Intern Med1984; 101: 34–40.
MichelP., JaninG., El YafiS., ChevallierP., GirardP., LavilleM., TrepoC.Improvement of immune response in dialysis patients to Hevac B vaccine after multiple injections of vaccine.Proc Eur Dial Transplant Assoc Eur Ren Assoc1985; 22: 1077–82.
20.
HadlerS.C., FrancisD.P., MaynardJ.E.Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.N Engl JMed1986; 315: 209–14.
21.
Recommendations of the Immunization Practices Advisory Committee (ACIP).Hepatitis B virus: a comprehensive strategy for elimination in the United States through universal childhood vaccination.MMWR1991; 40: 1–19.
22.
WoodR.C., MacDonaldK.L., WhiteK.E., HedbergC.W., HansonM., OsterholmM.T.Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers.JAMA1993; 270: 2935–9.
23.
ShawF.E., GuessH.A., RoetsJ.M., MohrF.E., ColemanP.J., MandelE.J., RoehmR.R., TalleyW.S., HadlerS.C.Effect of anatomic injection, site, age and smoking on the immune response to hepatitis b vaccination.Vaccine1989; 7: 425–30.
24.
WeberD.J., RutalaW.A., Sam saG.P., SantimawJ.E., LemonS.M.Obesity as a predictor of a poor antibody response to hepatitis b plasma vaccine.JAMA1985; 254: 3187–9.
25.
AlperC.A., KruskallM.S., Marcus-BagleyD., CravenD.E., KatzA.J., BrinkS.J., DiestagJ.L., AwdehZ., YunisE.J.Genetic prediction of non-responders to hepatitis B vaccine.N Engl J Med1989; 321: 708–12.
26.
SennesalJ.J., Van Der NiepenP., VerbeelenD.L.Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients.Kidney Int1991; 40: 121–8.
